Press Release Archive

 
03.27.2020 - Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact
*/ /*-->*/ /*-->*/
  • First in the industry sustainability bond provides opportunities to invest in projects supporting environmental sustainability and health of vulnerable populations
  • Supports United Nations Sustainable Development Goals (SDGs)

NEW YORK--(BUS

 
03.26.2020 - Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
*/ /*-->*/ /*-->*/

- Due to global impact of COVID-19 pandemic, transaction now expected to close in the second half of 2020 and Mylan’s EGM moved to June 30 -

 
03.24.2020 - U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis
*/ /*-->*/ /*-->*/

EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of age in the United States

 
03.18.2020 -  Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch
*/ /*-->*/ /*-->*/

 JADE COMPARE trial met all co-primary endpoints

Study included dupilumab in active control arm

Safety profile for abrocitinib consistent with previous studies

 
03.18.2020 - Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older
*/ /*-->*/ /*-->*/

20-valent pneumococcal conjugate vaccine demonstrated comparable safety and immunogenicity profile to licensed pneumococcal vaccines

 
03.18.2020 - Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns

Pfizer Inc. (NYSE: PFE) announced today that given the unique circumstances of the COVID-19 pandemic and Pfizer’s responsibility to prioritize the health and safety of colleagues and invited guests, the company will reschedule its planned March 31, 2020 Investor Day for a later date.

At this point, there isn’t a timetable for rescheduling the event and Pfizer will work within the context of appropriate guidance from health authorities to determine a future date.

About Pfizer: Breakthroughs That Change Patients’ Lives

 
03.18.2020 -  Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch

Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in adults with moderate to severe atopic dermatitis who were also on background topical therapy. The study also included an active control arm, dupilumab, a biologic treatment administered by subcutaneous injection, compared with placebo.

 
03.18.2020 - Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older

Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease.

 
03.17.2020 - Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2020.

 
03.17.2020 - Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
*/ /*-->*/ /*-->*/

Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection

Collaboration aims to accelerate global development of BNT162, leveraging expertise and resources of both companies

 
03.13.2020 - Pfizer Outlines Five-Point Plan to Battle COVID-19
*/ /*-->*/ /*-->*/

Chairman and CEO Albert Bourla Calls on Biopharma Industry to Collaborate on Combatting the Global Pandemic

NEW YORK--(BUSINESS WIRE)-- Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.

 
03.13.2020 - EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study

Rockland, MA and New York, US, March 13, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced an update from the Phase III JAVELIN Head and Neck 100 study evaluating avelumab in addition to chemoradiotherapy (CRT) versus standard-of-care CRT in patients with untreated locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

 
03.04.2020 - Susan Hockfield Elected to Pfizer’s Board of Directors
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and Compliance Committee and the Science and Technology Committee of Pfizer’s Board.

 
02.27.2020 - James Quincey Elected to Pfizer’s Board of Directors
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the election of James Quincey to its Board of Directors, effective immediately. Mr. Quincey, age 55, was also appointed to the Compensation Committee and the Science and Technology Committee of Pfizer’s Board.

 
02.27.2020 - Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
*/ /*-->*/ /*-->*/

- Pfizer’s Upjohn Division CFO Sanjeev Narula selected for leadership role at combined company -

 
02.27.2020 - Mylan and Pfizer Finalize Appointments to Viatris Board of Directors
*/ /*-->*/ /*-->*/

13 Inaugural Directors Bring Wide-Ranging Experience, Expertise and a Focus on Driving Shareholder Value

 
02.27.2020 - Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) today announced that Sanjeev Narula, current chief financial officer (CFO) of Upjohn, a division of Pfizer, has been named incoming CFO of Viatris, the new company that will result from the planned combination of Mylan and Upjohn. Upon closing, which is expected in mid-2020, Viatris will be a new champion for global health with a portfolio of approximately 3,000 brands and molecules and a commercial presence in 165 countries.

 
02.27.2020 - Mylan and Pfizer Finalize Appointments to Viatris Board of Directors

HERTFORDSHIRE, England, PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced the remaining appointees to the inaugural 13-member Board of Directors for Viatris, the new company that will result from the combination of Mylan and Upjohn, a division of Pfizer, which is expected to occur in mid-2020, subject to receipt of regulatory approvals, Mylan shareholder approval, and the satisfaction of other customary closing conditions.

 
02.25.2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the Cowen and Company 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 10:40 a.m. Eastern Standard Time.

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.